Mouna El Mehdi1, Saloua Takhlidjt1, Mélodie Devère1, Arnaud Arabo2, Marie-Anne Le Solliec1, Julie Maucotel2, Alexandre Bénani3, Emmanuelle Nedelec3, Céline Duparc1, Benjamin Lefranc1,4, Jérôme Leprince1,4, Youssef Anouar1, Gaëtan Prévost1,5, Nicolas Chartrel6, Marie Picot1. 1. Inserm, U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université, UNIROUEN, Rouen, France. 2. Department of Biological Resources (SRB), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université, UNIROUEN, Rouen, France. 3. Centre for Taste and Feeding Behaviour, CNRS (UMR6265), INRA (UMR1324), AgroSup Dijon, Université de Bourgogne Franche-Comté, Dijon, France. 4. Cell Imaging Platform of Normandy, Normandie Université, Rouen, France. 5. Department of Endocrinology, Diabetes and Metabolic Diseases, Normandie Université, UNIROUEN, Rouen University Hospital, Rouen, France. 6. Inserm, U1239, Laboratory of Neuronal and Neuroendocrine Differentiation and Communication (DC2N), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université, UNIROUEN, Rouen, France. nicolas.chartrel@univ-rouen.fr.
Abstract
AIMS/HYPOTHESIS: 26RFa (pyroglutamilated RFamide peptide [QRFP]) is a biologically active peptide that regulates glucose homeostasis by acting as an incretin and by increasing insulin sensitivity at the periphery. 26RFa is also produced by a neuronal population localised in the hypothalamus. In this study we investigated whether 26RFa neurons are involved in the hypothalamic regulation of glucose homeostasis. METHODS: 26Rfa+/+, 26Rfa-/- and insulin-deficient male C57Bl/6J mice were used in this study. Mice received an acute intracerebroventricular (i.c.v.) injection of 26RFa, insulin or the 26RFa receptor (GPR103) antagonist 25e and were subjected to IPGTTs, insulin tolerance tests, acute glucose-stimulated insulin secretion tests and pyruvate tolerance tests (PTTs). Secretion of 26RFa by hypothalamic explants after incubation with glucose, leptin or insulin was assessed. Expression and quantification of the genes encoding 26RFa, agouti-related protein, the insulin receptor and GPR103 were evaluated by quantitative reverse transcription PCR and RNAscope in situ hybridisation. RESULTS: Our data indicate that i.c.v.-injected 26RFa induces a robust antihyperglycaemic effect associated with an increase in insulin production by the pancreatic islets. In addition, we found that insulin strongly stimulates 26Rfa expression and secretion by the hypothalamus. RNAscope experiments revealed that neurons expressing 26Rfa are mainly localised in the lateral hypothalamic area, that they co-express the gene encoding the insulin receptor and that insulin induces the expression of 26Rfa in these neurons. Concurrently, the central antihyperglycaemic effect of insulin is abolished in the presence of a GPR103 antagonist and in 26RFa-deficient mice. Finally, our data indicate that the hypothalamic 26RFa neurons are not involved in the central inhibitory effect of insulin on hepatic glucose production, but mediate the central effects of the hormone on its own peripheral production. CONCLUSION/ INTERPRETATION: We have identified a novel mechanism in the hypothalamic regulation of glucose homeostasis, the 26RFa/GPR103 system, and we provide evidence that this neuronal peptidergic system is a key relay for the central regulation of glucose metabolism by insulin.
AIMS/HYPOTHESIS: 26RFa (pyroglutamilated RFamide peptide [QRFP]) is a biologically active peptide that regulates glucose homeostasis by acting as an incretin and by increasing insulin sensitivity at the periphery. 26RFa is also produced by a neuronal population localised in the hypothalamus. In this study we investigated whether 26RFa neurons are involved in the hypothalamic regulation of glucose homeostasis. METHODS: 26Rfa+/+, 26Rfa-/- and insulin-deficient male C57Bl/6J mice were used in this study. Mice received an acute intracerebroventricular (i.c.v.) injection of 26RFa, insulin or the 26RFa receptor (GPR103) antagonist 25e and were subjected to IPGTTs, insulin tolerance tests, acute glucose-stimulated insulin secretion tests and pyruvate tolerance tests (PTTs). Secretion of 26RFa by hypothalamic explants after incubation with glucose, leptin or insulin was assessed. Expression and quantification of the genes encoding 26RFa, agouti-related protein, the insulin receptor and GPR103 were evaluated by quantitative reverse transcription PCR and RNAscope in situ hybridisation. RESULTS: Our data indicate that i.c.v.-injected 26RFa induces a robust antihyperglycaemic effect associated with an increase in insulin production by the pancreatic islets. In addition, we found that insulin strongly stimulates 26Rfa expression and secretion by the hypothalamus. RNAscope experiments revealed that neurons expressing 26Rfa are mainly localised in the lateral hypothalamic area, that they co-express the gene encoding the insulin receptor and that insulin induces the expression of 26Rfa in these neurons. Concurrently, the central antihyperglycaemic effect of insulin is abolished in the presence of a GPR103 antagonist and in 26RFa-deficient mice. Finally, our data indicate that the hypothalamic 26RFa neurons are not involved in the central inhibitory effect of insulin on hepatic glucose production, but mediate the central effects of the hormone on its own peripheral production. CONCLUSION/ INTERPRETATION: We have identified a novel mechanism in the hypothalamic regulation of glucose homeostasis, the 26RFa/GPR103 system, and we provide evidence that this neuronal peptidergic system is a key relay for the central regulation of glucose metabolism by insulin.
Authors: Gregory J Morton; Richard W Gelling; Kevin D Niswender; Christopher D Morrison; Christopher J Rhodes; Michael W Schwartz Journal: Cell Metab Date: 2005-12 Impact factor: 27.287
Authors: Michael W Schwartz; Randy J Seeley; Matthias H Tschöp; Stephen C Woods; Gregory J Morton; Martin G Myers; David D'Alessio Journal: Nature Date: 2013-11-07 Impact factor: 49.962
Authors: Teppei Fujikawa; Eric D Berglund; Vishal R Patel; Giorgio Ramadori; Claudia R Vianna; Linh Vong; Fabrizio Thorel; Simona Chera; Pedro L Herrera; Bradford B Lowell; Joel K Elmquist; Pierre Baldi; Roberto Coppari Journal: Cell Metab Date: 2013-09-03 Impact factor: 27.287
Authors: Jennifer W Hill; Carol F Elias; Makoto Fukuda; Kevin W Williams; Eric D Berglund; William L Holland; You-Ree Cho; Jen-Chieh Chuang; Yong Xu; Michelle Choi; Danielle Lauzon; Charlotte E Lee; Roberto Coppari; James A Richardson; Jeffrey M Zigman; Streamson Chua; Philipp E Scherer; Bradford B Lowell; Jens C Brüning; Joel K Elmquist Journal: Cell Metab Date: 2010-04-07 Impact factor: 27.287
Authors: A Christine Könner; Ruth Janoschek; Leona Plum; Sabine D Jordan; Eva Rother; Xiaosong Ma; Chun Xu; Pablo Enriori; Brigitte Hampel; Gregory S Barsh; C Ronald Kahn; Michael A Cowley; Frances M Ashcroft; Jens C Brüning Journal: Cell Metab Date: 2007-06 Impact factor: 27.287